SEC Comment Letter 0000000000-23-012751 to bioAffinity Technologies, Inc. (BIAF)
bioAffinity Technologies, Inc.
Date: Nov. 21, 2023 · CIK: 0001712762 · Accession: 0000000000-23-012751
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275608
Letter
United States securities and exchange commission logo November 21, 2023 Maria Zannes Chief Executive Officer bioAffinity Technologies, Inc. 22211 W. Interstate 10, Suite 1206 San Antonio, Texas 78257 Re:bioAffinity Technologies, Inc. Registration Statement on Form S-3 Filed November 16, 2023 File No. 333-275608 Dear Maria Zannes: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jane Park at 202-551-7439 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Leslie Marlow, Esq.
Show Raw Text
United States securities and exchange commission logo
November 21, 2023
Maria Zannes
Chief Executive Officer
bioAffinity Technologies, Inc.
22211 W. Interstate 10, Suite 1206
San Antonio, Texas 78257
Re:bioAffinity Technologies, Inc.
Registration Statement on Form S-3
Filed November 16, 2023
File No. 333-275608
Dear Maria Zannes:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jane Park at 202-551-7439 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Leslie Marlow, Esq.